The cancer treatment market holds great potential and is being actively developed by many global pharmaceutical companies. The ideal anti-cancer therapy would be a targeted treatment that selectively tracks and eliminates cancer cells without affecting normal cells.

Antibody-drug conjugates (ADCs) are expected to become highly effective targeted therapies, as they use antibodies with very high specificity for cancer cells as carriers to deliver highly cytotoxic anticancer agents specifically to cancer cells.

• *High specificity for cancer cells
• *Powerful anti-cancer therapeutic effects

First-generation ADCs conjugate cytotoxic agents to non-specific sites on the antibody, making it difficult to achieve optimal safety and efficacy.

To overcome these limitations, many pharmaceutical companies are developing next-generation drug conjugation methods based on site-specific conjugation. Alteogen’s NexMab™ ADC technology enables site-specific drug conjugation through recombinant technology, allowing for the development of second-generation ADC therapeutics with superior stability, efficacy, and cost-effectiveness.